<DOC>
	<DOCNO>NCT00541749</DOCNO>
	<brief_summary>This Phase I , randomize , placebo-controlled , double-blind , dose-escalation study single repeat dos rhuMAb IFNalpha , administer SC IV route , adult Systemic Lupus Erythematosus .</brief_summary>
	<brief_title>A Study rhuMAb IFNalpha Adults With Systemic Lupus Erythematosus</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<criteria>For patient reproductive potential ( male female ) , use reliable mean contraception ( e.g. , hormonal contraceptive , patch , vaginal ring , intrauterine device , physical barrier ) throughout participation study Diagnosis SLE accord current American College Rheumatology ( ACR ) criteria Disease duration â‰¥ 1 year ( first diagnosis physician ) Current immunity measles , mumps , rubella , varicella , evidence positive IgG titer time screen Current vaccination influenza unless contraindicate investigator 's judgment Normal Pap smear within applicable time interval recommend current American Cancer Society guideline Presence active lupus nephritis Presence active central nervous system ( CNS ) disease require treatment highdose corticosteroid immunosuppressive agent Presence active vasculitis require treatment History arterial venous thromboses within 12 month screen Moderate severe anemia , thrombocytopenia , neutropenia Any manifestation likely require , investigator 's judgment , treatment highdose corticosteroid addition immunosuppressive regimen course trial Pregnancy lactation Lack peripheral venous access History alcohol substance abuse within 6 month screen History severe allergic anaphylactic reaction antibody fusion protein Evidence significant uncontrolled concomitant diseases Significant laboratory electrocardiogram ( ECG ) abnormalities Evidence clinically significant abnormality chest Xray Severly impair renal function Impaired hepatic function Poorly control diabetes Conditions SLE could require treatment corticosteroid History malignancy except completely excise basal cell carcinoma Congenital immune deficiency Positive test antibody HIV , hepatitis B ( HBS antigen , antiHBC ) C Positive IgM antibody titer presence negative IgG titer EpsteinBarr virus ( EBV ) cytomegalovirus ( CMV ) Frequent recurrence herpes lesion Episode shingle within one year screen Positive screen test latent mycobacterium tuberculosis infection History severe systemic bacterial , fungal , viral , parasitic infection within year prior screen Any current recent sign symptom infection Received antibiotic orally ( PO ) 30 day prior screen IV antibiotic 60 day prior screen Received live vaccine within 30 day prior screen Has hospitalize within 30 day prior screen Received &gt; 20 mg/day prednisone &gt; 3 day 30 day prior screen Received azathioprine , methotrexate , mycophenolate mofetil , cyclosporine , tacrolimus , sirolimus , pulse dose corticosteroid , intravenous immunoglobulin ( IVIG ) , transfusion within 6 month prior screen Received cyclophosphamide within 2 year prior screen Received monoclonal antibody 12 month prior screen Previously receive investigational treatment direct interferon alpha Received Bcell deplete therapy ( e.g. , antiCD20 , antiCD22 ) Received investigational treatment 30 day prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>SLE</keyword>
</DOC>